Skip to content
WeighLab
Menu
Ranked #103 · Grade C

Hers review

Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Visit Hers Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$199/mo (starting dose, compounded)
Tirzepatide
$299/mo (starting dose, plus a separate fee, brand-name)
Coverage
All 50 states
Brand-name
Yes

Semaglutide · modeled / year

$2,388

Tirzepatide · modeled / year

$3,588

The Index scorecard

Hers scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month59/100
Price Transparency78/100
Nationwide Access86/100
Formulation Options79/100
Clinical Oversight71/100
Contract Flexibility41/100

Where the value is

  • Compounded GLP-1 access

The tradeoffs

  • Limited public information on program details

The bottom line

Best for: Cost-first shoppers who want mainstream telehealth GLP-1 access. Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Ranked #103 of 492 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 491 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Hers.

The 18 programs nearest this one

Pricing, states and verification reflect Hers's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Hers's site. Not medical advice; see our disclosure.

← Back to the value leaderboard